Recent advancements allow for the analysis of plasma, serum, saliva, and urine metabolites, which can offer new avenues for understanding the relationship between hormone receptor status and metabolite biomarkers in breast cancer subtyping [17]. Here, NR4A1 is linked to breast carcinoma.